{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "Carmen J. Pirollo expected his latest attempt to lose weight would take a while. At 5 feet 11 inches, he wanted to weigh 180 pounds, down from 260. A veteran dieter -- ''I've lost and gained a whole person in my lifetime'' -- he knew it would not be easy. But while Mr. Pirollo, a 55-year-old sixth-grade teacher in Haddon Heights, N.J., says he is healthy, he worries that his excess weight might take a toll on his health. And, of course, he wants to look good.", "headline": {"main": "Health and Money Issues Arise Over Who Pays for Weight Loss"}, "abstract": "Medicare advisers will assess safety, efficacy and cost of increasingly popular method of weight loss--surgery--as first step in new policy that could lead to use of federal money to cover range of other obesity treatments; coverage by Medicare and other insurers may increase at time when evidence suggests that few obese people can lose significant amounts of weight in long term, and some obesity researchers question fundamental idea that losing weight improves health; reason for dearth of information on long-term effects of weight loss is that very few people keep weight off; currently, Medicare will pay for weight-loss surgery when patients suffer other problems associated with condition, like diabetes; new talks will discuss covering treatment for those who are simply obese; agency wants to determine if obesity treatments help people lose weight and improve their health; bariatric surgery costs $30,000 to $40,000; cost to Medicare for such coverage has not been determined; 61 million Americans are termed obese, including 9 million of Medicare age, 65 and older; photo (M)", "print_page": "1", "word_count": 1903, "_id": "4fd2801b8eb7c8105d84ad1b", "snippet": "In November, Medicare's advisers will assess the safety, efficacy and cost of a popular method of weight loss: surgery.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/09/30/business/30obese.html", "multimedia": [{"url": "images/2004/09/30/business/30obsese.gif", "subtype": "thumbnail", "legacy": {"hasthumbnail": "Y", "thumbnailheight": 75, "thumbnail": "images/2004/09/30/business/30obsese.gif"}, "type": "image", "height": 75}], "subsection_name": null, "keywords": [{"name": "glocations", "value": "UNITED STATES"}, {"name": "organizations", "value": "WEIGHT WATCHERS"}, {"name": "subject", "value": "DIET AND NUTRITION"}, {"name": "subject", "value": "WEIGHT"}, {"name": "subject", "value": "HEALTH INSURANCE AND MANAGED CARE"}, {"name": "subject", "value": "DIABETES"}, {"name": "subject", "value": "FINANCES"}, {"name": "subject", "value": "PRICES (FARES, FEES AND RATES)"}, {"name": "subject", "value": "OBESITY"}, {"name": "subject", "value": "MEDICARE"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "BUDGETS AND BUDGETING"}, {"name": "subject", "value": "SURGERY AND SURGEONS"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Gina", "rank": 1, "lastname": "KOLATA"}], "original": "By GINA KOLATA"}, "document_type": "article", "pub_date": "2004-09-30T00:00:00Z", "section_name": "Front Page; Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "The incidence of a rare but serious side effect associated with Eprex, an anemia drug from Johnson & Johnson that is sold overseas, has been sharply reduced by changes in the packaging and administration of the drug, two teams of scientists said yesterday. But the damage to Johnson & Johnson's sales might not be reversed as easily. And the incident has raised questions about the monitoring of drugs already on the market and about the safety of drug imports.", "headline": {"main": "Trouble With Anemia Drug Is Reduced, but Issues Remain"}, "abstract": "Two studies find that rare but serious side effect associated with Eprex, anemia drug from Johnson & Johnson that is sold overseas, has been sharply reduced by changes in packaging and administration of drug; virtually identical US drugs, genetically engineered version of erythropoietin or EPO, caused far fewer cases of side effect, pure red cell aplasia, and two studies suggest explanation; damage to Johnson & Johnson's sales might not be reversed easily, and incident has raised questions about monitoring of drugs already onmarket and about safety of drug imports (M)", "print_page": "11", "word_count": 666, "_id": "4fd23cb38eb7c8105d7d23d7", "snippet": "The incidence of a rare but serious side effect associated with Eprex has been sharply reduced by changes in the packaging and administration of the drug.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/09/30/business/30blood.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "JOHNSON & JOHNSON INC"}, {"name": "subject", "value": "INTERNATIONAL TRADE AND WORLD MARKET"}, {"name": "subject", "value": "CONTAINERS AND PACKAGING"}, {"name": "subject", "value": "GENETICS AND HEREDITY"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "EPREX (DRUG)"}, {"name": "subject", "value": "ANEMIA"}, {"name": "subject", "value": "ERYTHROPOIETIN (EPO)"}, {"name": "subject", "value": "GENETIC ENGINEERING"}, {"name": "subject", "value": "DEATHS (OBITUARIES)"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Andrew", "rank": 1, "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "document_type": "article", "pub_date": "2004-09-30T00:00:00Z", "section_name": "Business"}], "meta": {"hits": 2, "offset": 0, "time": 40}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}